European Cannabis Market Leader Bloomwell Group Secures $10 Million Investment

Largest Seed Funding Ever Received In European Cannabis Market

– U.S. growth capital provider Measure 8 Venture Partners is the lead investor

– Curaleaf executive chairman Boris Jordan joins board

– Investment ushers in a new era of “natural-based medicine.”

– Showcases Germany as the leading European market for medical cannabis

FRANKFURT, Germany, Oct. 18, 2021 /PRNewswire/ — The Bloomwell Group has successfully closed a seed funding round of over $10 millionthe highest publicly known seed investment for a European cannabis company to date. The lead investor is U.S. growth capital provider Measure 8 Venture Partners, specialists in cannabis industry investments. In addition, business angel Dr. Reinhard Meier is reinvesting among other investors through his Venture Capital Investors fund; and Mr. Weber of FPS acted as legal advisor to Bloomwell.

Concurrent with the announcement, the Bloomwell Group, which includes Algea CareEurope’s leading telemedicine company for medical cannabis in terms of patient numbers, is repositioning itself as a holding company, allowing it to build, invest or acquire cannabis companies.

“With Bloomwell, we are revolutionizing healthcare through digitalization and the potential of medical cannabis as well as other natural medicines. Our portfolio companies will radically focus on a consumer-centric approach along the entire value chain of medical cannabis, with the exception of cultivation. The era of natural-based medicine begins now, and Bloomwell is taking the lead,” said Niklas Kouparanis, CEO & Co-Founder of Bloomwell Group. 

Bloomwell Group has grown to 160 employees within a year, with projected revenues of five million euros in 2021. In addition to Niklas Kouparanis, CEO, entrepreneur, and cannabis pioneer, the board is strengthened by telemedicine veteran Dr. Reinhard Meier, who, as founder-led Teleclinic to an exit, Co-Founder Samuel Menghistu and Boris Jordan, founding partner of Measure 8 Venture Partners.

The accomplished board covers medicine, digitalization, cannabis, Investment, and brand building across various market sectors.

  • Dr. Reinhard Meier, Director of Radiology at Westpfalz Klinikum, previously founded and invested in several medical companies and initiated several V.C. funds.
  • Boris Jordan, With the $285M acquisition of EMMAC, Curaleaf is the first and only MSO to have a meaningful presence in Europe. Jordan is considered one of the most renowned cannabis experts in North America. It has been responsible for the operations of Curaleaf, a global publicly traded cannabis company, and venture investments in the cannabis space via Measure 8 Ventures.
  • Niklas Kouparanis, a serial entrepreneur and a pioneer in the European medical cannabis industry.
  • Samuel Menghistu, spearheading the intersection of banking, investments, M&A Transactions, and IPOs for over six years.

“Many of the high expectations of both investors and global corporations within the European cannabis industry have not been fulfilled since the enactment of the ‘Cannabis Law’ in March 2017, even though the market has continued to grow steadily. With Bloomwell, we have shown within just one year how much can be achieved through entrepreneurial finesse. Moreover, the nascent European cannabis industry is full of potential for Bloomwell’s future development. While the market is consolidating elsewhere, all signs point towards growth and expansion through the combination of cannabis, innovation, digitalization, and a radical D2C or direct-to-patient approach,” said Anna-Sophia Kouparanis, Co-Founder of the Bloomwell Group.

Germany is the leading European market for medical cannabis, and the Bloomwell Group has proven within one year that it can identify and scale innovative solutions in this new growth market for the benefit of patients. Cannabis has a bright future in Europe, and we look forward to supporting and working with the Bloomwell Group as they continue to scale,” said Boris Jordan, Founding Partner of Measure 8 Venture Partners and Executive Chairman of Curaleaf.   

“Digitalization is the key to finally putting patients at the center of an inefficient healthcare system. Algea Care, a portfolio company of Bloomwell, has already proven that it has the expertise and clout to improve the well-being and everyday life of thousands of patients in a highly regulated sector through medical cannabis and digitalization as well as an immensely high service standard,” said Dr. Reinhard Meier.

About Bloomwell Group

The Bloomwell Group is a holding company for medical cannabis companies and potentially for companies in a recreational market that may be legal in the future. The mission is to build, acquire and invest in ESG healthcare companies along the entire value chain, except cultivation. In doing so, Bloomwell Group relies on a patient-centric D2C approach to set up a strong, revolutionizing, and streamlined Patient Journey to change healthcare for the better. The combination of natural medicines and digitalization is a journey back to the roots of healthcare with 21st-century tools. The green revolution in healthcare starts now, and Bloomwell is taking the lead:

About Measure 8 Venture Partners

Founded in 2018, Measure 8 Venture Partners was created by Boris Jordan to capitalize on the emergence of the U.S. and the global cannabis industry and was named by Business Insider as the most active cannabis V.C. fund during 2020.

Press contact:
Lori Rosen
[email protected]

European Cannabis Market Leader Bloomwell Group Secures $10 Million Investment